PT-141, known in scientific literature as bremelanotide, is a synthetic peptide that acts on receptors in the brain rather than on blood vessels. It is the active molecule in an FDA approved prescription drug covering one narrowly defined female diagnosis, and it remains an open research question well beyond that indication. What follows is the published evidence, its limits, and how the compound is classified today.
Key Takeaways
- Bremelanotide is FDA approved under the brand name Vyleesi for acquired, generalized HSDD in premenopausal women. Approval came on June 21, 2019, making it the first FDA approved as-needed injectable treatment for the diagnosis.
- PT-141 activates melanocortin receptors in the central nervous system, acting on brain pathways rather than raising blood flow the way traditional ed medications do.
- Phase 3 clinical trials in 1,247 patients recorded statistically significant but modest gains in sexual desire scores across 24 weeks.
- Nausea is the most common side effect. Labeling also documents transient blood pressure increases, heart rate decreases, and skin pigmentation changes.
- PT-141 is not FDA approved for men, for postmenopausal women, or to improve sexual performance. Material sold by AZOTH is supplied for laboratory research use only.
What PT-141 Actually Is
PT-141 is a synthetic peptide analog of alpha-melanocyte-stimulating hormone, a signaling molecule the body already produces. It emerged from work on melanotan II, a compound originally studied for its effect on melanin in skin.
From Skin Pigmentation Work to Sexual Medicine
Investigators noticed effects on sexual behavior in animal models that had nothing to do with skin color. Basic research at Palatin Technologies isolated the fragment now called bremelanotide, and clinical researchers took it from there.
Why the Molecule Interested Researchers
Every approved drug for erectile dysfunction at the time worked on the vascular side. PT-141 worked somewhere else entirely, which made it a genuinely different experiment rather than another entry in a crowded category.
How PT-141 Works Through Melanocortin Receptor Activity
Bremelanotide is a non-selective agonist at several melanocortin receptor subtypes, with MC1R and MC4R binding considered most relevant at therapeutic doses.1 Melanocortin signaling in the body also touches pigmentation, appetite, and inflammation, which is part of why effects show up in unrelated systems.
Brain Pathways Instead of Blood Vessels
MC4R-expressing neurons sit throughout the central nervous system. Activating them appears to influence brain pathways tied to sexual desire and mental arousal. The FDA label is direct about this: the exact mechanism by which the drug improves symptoms is unknown.
Why This Is Not a Blood Flow Drug
Unlike medications that relax blood vessels to raise blood flow into genital tissue, PT-141 does not act peripherally. A 2006 crossover study measured vaginal pulse amplitude and found changes in subjective sexual response without a matching change in local blood flow, which pointed hard at a central mechanism.2
Independence From Hormone Levels
PT-141 does not appear to work by shifting hormone levels. That separates it from testosterone-based approaches and from other therapies aimed at hormonal changes around perimenopause.
What Clinical Trials Found About Desire
Two identical phase 3, randomized, double blind, placebo-controlled trials known as RECONNECT form the core evidence base.
What the RECONNECT Studies Measured
Participants were premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Each received 1.75 mg of bremelanotide or placebo, as needed, over 24 weeks. Co-primary endpoints were the Female Sexual Function Index desire domain and a distress item.3
What the Numbers Showed
Both trials found statistically significant increases in sexual desire and statistically significant reductions in distress related to low sexual desire compared with placebo. Roughly 25% of patients on the drug reached a desire score increase of 1.2 or more, against about 17% on placebo.4
The Honest Reading of That Data
Effect sizes were small. The number of satisfying sexual events did not increase meaningfully. These are real, replicated, statistically significant results, and they are also modest. Both things are true.
Longer Follow-Up
An open-label extension tracked patients for up to 52 additional weeks and reported no new safety signals, though discontinuation for tolerability was common.5
FDA Approved Status of Bremelanotide Injection
The FDA approved bremelanotide injection on June 21, 2019, marketed as Vyleesi.
What the Approval Covers
The indication is narrow. It covers treatment of HSDD in premenopausal women where the low sexual desire is acquired, generalized, and causes marked distress. Approved dosing is 1.75 mg by the subcutaneous route into the abdomen or thigh, at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours and no more than eight doses per month. It is used as needed before sexual activity rather than on a daily schedule.
What the Approval Does Not Cover
Labeling states plainly that the drug is not indicated for HSDD in postmenopausal women, not indicated for men, and not for use to improve sexual performance. Prescribing guidance also directs clinicians to stop treatment after eight weeks if a patient reports no change.
Prescription Versus Research Material
Vyleesi is a prescription product dispensed through pharmacies with healthcare professional oversight. Research-grade PT-141 sold as a laboratory compound is a different thing with a different legal status, and it carries no approval for human use.
Hypoactive Sexual Desire Disorder: The Diagnosis Behind the Data
HSDD is the most prevalent of the female sexual dysfunctions, affecting an estimated 10% of women of reproductive age.6 The defining feature is not low libido by itself but low libido that the person finds distressing.
Distress Is the Diagnostic Line
Many women have periods of reduced sexual interest and are untroubled by it. That is not a disorder. Talking about sex with a clinician is uncomfortable for plenty of patients, which is one reason the condition goes underreported.
Ruling Out Relationship Problems
The label excludes cases where relationship problems explain the picture. Relationship issues, conflict, and loss of attraction produce low desire that no treatment addresses.
Ruling Out Medical Problems and Medication Effects
Diagnosis also requires ruling out co-existing medical problems, psychiatric conditions, mood disorders, and the effects of certain medications. Antidepressants and some blood pressure medications suppress desire directly. So do hormonal changes tied to contraception or thyroid dysfunction.
Erectile Dysfunction Research and Off Label Interest
Early clinical studies examined bremelanotide for erectile dysfunction, including in men who had not responded to sildenafil. That development path was discontinued, largely over blood pressure findings with the intranasal formulation.
Where Off Label Use Stands
PT-141 is not FDA approved for male sexual dysfunction. Off label prescribing and compounded versions circulate anyway, often marketed toward many men seeking a treatment for erectile function beyond the standard options. The controlled evidence for erectile function in most men is thin next to the female desire data.
Why the Off Label Gap Matters
Off label use of an approved product at least happens under a healthcare professional’s supervision. Self-directed use of unapproved material does not, and that is a meaningful difference in risk.
Blood Pressure and Cardiovascular Disease Signals
This is the part of the safety profile that deserves the most attention.
Documented Cardiovascular Effects
Bremelanotide injection produces transient increases in blood pressure and reductions in heart rate, typically peaking within a few hours of dosing. Mean systolic blood pressure rises of roughly 6 mmHg were recorded in trials.
Why Cardiovascular Disease Is an Exclusion
Labeling contraindicates use in uncontrolled high blood pressure and in known cardiovascular disease. The blood pressure effect is small in healthy patients and potentially not small in patients with existing cardiovascular disease. Trials screened those patients out, so the data simply does not exist for them.
The Documented Safety Profile
Melanocortin receptor agonists carry a characteristic side effect pattern, and PT-141 is no exception.
Nausea, Flushing, and Headache
The most common side effects across trials were nausea, flushing, and headache, each occurring in 10% or more of patients. Nausea was frequently reported after the first dose and often decreased with later doses.
Skin Darkening
MC1R sits on melanocytes, so activating it drives melanin production. Focal hyperpigmentation of the face, gums, and breast skin occurred in trials and was more common with daily dosing than as-needed use. Skin changes did not always resolve after stopping.
Injection Site Reactions
Injection site reactions were reported regularly. Local irritation at the injection site is among the more predictable findings for any subcutaneous route compound.
Slow Gastric Emptying
PT-141 can slow gastric emptying, changing how quickly the body absorbs oral medications taken around the same time. This is why labeling flags interactions rather than treating the drug as pharmacologically isolated.
Low Libido Is Not One Condition
Low desire has many drivers: sleep debt, mood, medications, hormonal changes, chronic illness, and the state of a relationship. Sexual dysfunction has psychological, vascular, hormonal, and relational causes, and a compound acting on one receptor family does not address most of them. Desire and the physical mechanics of sex are different problems.
What the Research Has Not Settled
Long term safety past the extension studies is not characterized. Data on male sexual dysfunction is limited. Compounded versions are not tested to the standards applied to approved medications, and purity varies widely across suppliers.
Why Researchers Choose PT-141 from AZOTH
AZOTH supplies bremelanotide as a research compound for laboratory use only, not for human consumption or any therapeutic application. Every batch is U.S. made and verified at 99%+ purity, with third-party certificates of analysis available alongside full product specifications, CAS number, molecular formula, and storage guidance. Bremelanotide sits at an unusual point in the peptide literature: a molecule with a completed phase 3 program, a published safety profile, and an approved reference product, which makes it a well-documented subject for melanocortin pathway research. AZOTH pairs that documentation with educational resources written for researchers and science-focused customers who prefer primary literature to marketing copy. Verified purity, transparent testing records, and scientific context are what separate AZOTH from commodity research compound vendors.
What the Research Says
Bremelanotide has a real evidence base and a narrow one. Two large trials showed it produces statistically significant improvements in sexual desire and related distress for premenopausal women with a specific diagnosis, and regulators concluded the benefit of treatment outweighed the risk for that group. The effect is modest, nausea is common, and the blood pressure signal rules out patients with cardiovascular disease.
Outside that indication, the picture thins fast. Claims about libido in men, sex drive generally, or sexual health broadly outrun what has been tested. Anyone considering the approved product should work through a healthcare professional, and anyone sourcing research material should understand it is exactly that.
Frequently Asked Questions
Yes, as Vyleesi, for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women only. It is not FDA approved for men, postmenopausal women, or general sexual performance use.
Traditional ed medications work on blood flow in genital tissue. Those medications relax blood vessels. PT-141 instead acts on melanocortin receptor targets in the brain, which is why it is described as a central rather than peripheral mechanism.
Nausea, flushing, headache, and injection site reactions. Skin darkening and short-lived blood pressure changes are also documented in labeling.
Trials only enrolled patients meeting HSDD criteria, so there is no evidence base for general low libido. Sexual health concerns should be assessed by a clinician first.
References
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf ↩︎
- https://www.sciencedirect.com/science/article/abs/pii/S1743609515313631 ↩︎
- https://pubmed.ncbi.nlm.nih.gov/31599840/ ↩︎
- https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000Approv.pdf ↩︎
- https://pubmed.ncbi.nlm.nih.gov/31599847/ ↩︎
- https://www.ncbi.nlm.nih.gov/books/NBK603746/ ↩︎
